Evan Dellon leads phase 3 trial on Cendakimab for Eosinophilic Esophagitis
The NC TraCS Clinical & Translational Research Center (CTRC) provided space and highly skilled nursing staff for this phase 3 clinical trial.
Evan Dellon, MD, MPH, a Professor in the Division of Gastroenterology and Hepatology at UNC and the Director of the Center for Esophageal Diseases and Swallowing, led a Phase 3 Trial on using Cendakimab for Eosinophilic Esophagitis (EoE). His study was published in NEJM Evidence with positive findings.
Cendakimab is a high-affinity monoclonal antibody that blocks IL-13 by preventing interaction with IL-13 receptors alpha-1 and alpha-2. In Dr. Dellons’ study, Cendakimab demonstrated statistically significant improvements in symptoms, histologic response, and endoscopic features of EoE as compared to the placebo group. The study involved over 400 participants across 15 countries.
The study’s results suggest Cendakimab offers clinically meaningful improvements in symptoms, histology, and endoscopic outcomes for patients with EoE. Importantly, the tested therapy demonstrated a manageable safety profile, reinforcing IL-13 as a viable therapeutic target in type 2 inflammatory diseases.
Read the full evidence report at evidence.nejm.org.
Originally published at med.unc.edu/medicine/news.